Search

Vetoquinol SA

Open

BrancheGesundheitswesen

74.2 -0.54

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

72.8

Max

75

Schlüsselkennzahlen

By Trading Economics

Einkommen

-9.8M

25M

Verkäufe

-17M

258M

KGV

Branchendurchschnitt

15.353

37.003

Dividendenrendite

1.13

Gewinnspanne

9.734

Angestellte

2,497

EBITDA

-12M

48M

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

1.13%

2.25%

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

14M

924M

Vorheriger Eröffnungskurs

74.74

Vorheriger Schlusskurs

74.2

Nachrichtenstimmung

By Acuity

50%

50%

142 / 373 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

Vetoquinol SA Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

2. Nov. 2025, 22:13 UTC

Ergebnisse

Westpac Raises Dividend Despite 1% Slip in Annual Profit -- Update

2. Nov. 2025, 21:23 UTC

Ergebnisse

Westpac Raises Dividend Despite 1% Slip in Annual Profit

2. Nov. 2025, 23:43 UTC

Market Talk

Gold Falls on Reports of China's Finance Ministry Ending Tax Incentive for Gold Sales -- Market Talk

2. Nov. 2025, 23:34 UTC

Market Talk

Oil Rises as OPEC+ Signals Output-Increase Pause -- Market Talk

2. Nov. 2025, 21:00 UTC

Ergebnisse

Westpac Has Set Tech Overhaul Goals and Will Share Progress, CEO Says>WBC.AU

2. Nov. 2025, 21:00 UTC

Ergebnisse

Westpac Is Now Executing on Tech Overhaul, CEO Says>WBC.AU

2. Nov. 2025, 21:00 UTC

Ergebnisse

Westpac Has Completed Tech Overhaul's Discovery and Planning Phases, CEO Says >WBC.AU

2. Nov. 2025, 20:55 UTC

Ergebnisse

Westpac FY Australia Mortgage Lending Up 5% on Year>WBC.AU

2. Nov. 2025, 20:55 UTC

Ergebnisse

Westpac FY Institutional Lending Up 17% on Year>WBC.AU

2. Nov. 2025, 20:55 UTC

Ergebnisse

Westpac FY Business Lending Up 15% on Year>WBC.AU

2. Nov. 2025, 20:46 UTC

Ergebnisse

Westpac Expects Completion in 2H of FY 2026>WBC.AU

2. Nov. 2025, 20:46 UTC

Ergebnisse

Westpac Expects CET1 Capital Ratio to Rise by 20 Basis Points>WBC.AU

2. Nov. 2025, 20:45 UTC

Ergebnisse

Westpac: Sale Is at Slight Premium to Expected Gross Loan Value at Completion>WBC.AU

2. Nov. 2025, 20:44 UTC

Ergebnisse

Westpac Selling to Consortium Including KKR, Pimco and Pepper Money>WBC.AU

2. Nov. 2025, 20:43 UTC

Ergebnisse

Westpac Agrees to Sell A$21.4B Rams Mortgage Portfolio>WBC.AU

2. Nov. 2025, 20:42 UTC

Ergebnisse

Westpac FY Impairment Provisions A$4.99B Vs. A$5.10B>WBC.AU

2. Nov. 2025, 20:41 UTC

Ergebnisse

Westpac FY Net Profit Ex-Notable Items A$7.0B, Down 2% on Year>WBC.AU

2. Nov. 2025, 20:40 UTC

Ergebnisse

Westpac FY Customer Deposits A$723.0B Vs. A$673.6B>WBC.AU

2. Nov. 2025, 20:39 UTC

Ergebnisse

Westpac FY Total Loans A$851.85B Vs. A$806.77B>WBC.AU

2. Nov. 2025, 20:37 UTC

Ergebnisse

Westpac FY24 Impairment Charges 5 Bps of Loans Vs. 7 Bps in FY25>WBC.AU

2. Nov. 2025, 20:37 UTC

Ergebnisse

Westpac FY Operating Expenses A$11.92B Vs. A$10.94B>WBC.AU

2. Nov. 2025, 20:37 UTC

Ergebnisse

Westpac FY Non-Interest Income A$3.00B Vs. A$2.835B>WBC.AU

2. Nov. 2025, 20:36 UTC

Ergebnisse

Westpac FY Net Interest Income A$19.38B Vs. A$18.75B>WBC.AU

2. Nov. 2025, 20:35 UTC

Ergebnisse

Westpac FY CET1 Level 2 Capital Ratio 12.5% Vs. 12.5%>WBC.AU

2. Nov. 2025, 20:35 UTC

Ergebnisse

Westpac FY Net Interest Margin 1.94% Vs. 1.95%>WBC.AU

2. Nov. 2025, 20:35 UTC

Ergebnisse

Westpac Raises Dividend to A$0.77 Vs. A$0.76 >WBC.AU

2. Nov. 2025, 20:34 UTC

Ergebnisse

Westpac FY Rev A$22.38B Vs. A$21.59B >WBC.AU

2. Nov. 2025, 20:33 UTC

Ergebnisse

Westpac FY Net A$6.92B Vs. Net A$6.99B >WBC.AU

2. Nov. 2025, 14:27 UTC

Ergebnisse

Berkshire Operating Profits Rose 33% in Third Quarter. There Were No Stock Buybacks. -- Barrons.com

2. Nov. 2025, 14:25 UTC

Ergebnisse

Warren Buffett Is Leaving Berkshire Hathaway in Great Shape for His Successor After Profit Results -- Barrons.com

Vetoquinol SA Prognose

Rating-Konsens

By TipRanks

0 ratings

0

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

72.6 / 75.1Unterstützung & Widerstand

Kurzfristig

Bearish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

142 / 373 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Vetoquinol SA

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.
help-icon Live chat